Study M913
Study name | Kamishikiryo T 2022 |
Title | Left DLPFC activity is associated with plasma kynurenine levels and can predict treatment response to escitalopram in major depressive disorder |
Overall design | The aim of this study was to determine the relationship between regional brain activity at rest and blood metabolites related to treatment response to escitalopram to identify the characteristics of depression that respond to treatment. Blood metabolite levels and resting-state brain activity were measured in patients with moderate to severe depression (depression group, n = 65) before and after 6-8 weeks of treatment with escitalopram, and these were compared between responders (>50% reduction in the HRSD score; responder group, n = 32) and nonresponders (nonresponder group, n = 33) to treatment. The relationship between plasma metabolites and brain activity related to treatment responsiveness were examined in patients and healthy controls (control group, n = 36). |
Study Type | Type1; Type2; Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 >= 14 |
Sample size | 101 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; CE-MS: Agilent 7100 CE-6230 TOFMS (Agilent Technologies, Palo Alto, CA, USA); |
PMID | |
DOI | |
Citation | Kamishikiryo T, Okada G, Itai E, et al. Left DLPFC activity is associated with plasma kynurenine levels and can predict treatment response to escitalopram in major depressive disorder. Psychiatry Clin Neurosci. 2022 May 11. |
Metabolite | L-Phenylalanine; L-Tryptophan; L-Valine; L-Leucine; L-Isoleucine; L-Asparagine; L-Tyrosine; L-Arginine; Choline; Dimethylglycine; |
